SlideShare ist ein Scribd-Unternehmen logo
1 von 2
Downloaden Sie, um offline zu lesen
Unlocking Data

            for Profitable

                    Clinical Development
                                           Staffan Gestrelius: Scientists need to         then all of a sudden you have to focus
                                           probe and analyze data the way the             on the patient and what genetic
                                           financial sector does. To make better          patterns or biomarkers he reacts to, this
                                           decisions and learn more about their           will be an important turning point in
                                           compounds and patients, they must              drug development.
                                           unlock data throughout the study and
                                           not just at the end. This will become
                                           even more important with personalized
                                           medicine.

                                           How can clinical data become a
                                                                                               Knowledge
                                           knowledge asset?
                                                                                            directly impacts
                                           Jerker Ringstrom: One of the most
                                           important words in this space is                    profitability
                                           “knowledge”. To turn data into a
                                           knowledge asset, it must be put into
                                           perspective. Scientists need constant
                                           feedback when deciding whether to              Can it help scientists        be   more
                                           continue with a program or to make             innovative? How?
                                           amendments.
                                                                                          Jerker Ringstrom: Scientists can get
                                           If you look at a clinical trial protocol, it   new ideas for indications by better
                                           usually mirrors the situation of the           analyzing data. More drugs today are
                                           study six to eight months before it            being used in new formulations and for
                                           ended. This means there was time to            new indications, but finding these new
Interview with: Staffan Gestrelius,        make valuable changes to the design            indications is proving to be challenging.
President and Chief Executive              and improve the quality of the trial.
Officer & Jerker Ringstrom, Head of                                                       How is this         approach       more
Business Development, Capish               How could this enhance safety?                 profitable?

                                           Staffan Gestrelius: If you have a system       Staffan Gestrelius: This will be a
Scientists must unlock and analyze data    that continuously watches over patients        knowledge game. It will become crucial
throughout the clinical trial, according   and gives you access to graphs and             to know everything about a specific
to Staffan Gestrelius, President and       statistics, you can keep track of adverse      drug. This approach is more profitable
Chief Executive Officer and Jerker         events and drug associated adverse             because people are not willing to pay for
Ringstrom, Head of Business                effects. The earlier this is done, the         a drug that only has a 50 per cent
Development, Capish. From a solution       better.                                        chance of curing them. The reason why
provider company at the marcus evans                                                      many companies are troubled today is
Evolution Summit 2012, in North            Jerker Ringstrom: This also helps              because they do not have good enough
America and the Evolution Summit           pharmaceutical companies be patient            treatments.
2012 in Europe, Gestrelius and             centric. When you develop a new drug,
Ringstrom discuss how knowledge            you need to come up with a diagnostic          Knowledge directly impacts profitability.
directly impacts the profitability of      tool. The patient plays a more central         Pharmaceutical companies should focus
clinical development.                      role than before, as the diagnosis will be     more on knowledge than on showing
                                           the torch through the darkness. I              that the drug is not dangerous, simply
What role can Business Intelligence        emphasize darkness, because when you           to get it approved by the FDA. This will
tools play in clinical development?        focus on means and standard deviations         not be enough.
For more information please send an email to info@marcusevanscy.com or visit
  The      Pharma        Network          -       the event websites below:
  marcus evans Summits group
  delivers peer-to-peer information               Evolution Summit 2012 - North America: www.evolutionsummit.com
  on strategic matters, professional
  trends       and      breakthrough              Evolution Summit 2012 - Europe: www.evolution-summit.com
  innovations.




                                                    Contact
  Please note that the Summit is a                  Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus                   evans, Summits
  closed     business   event     and   the         Division
  number      of   participants    strictly
                                                    Tel:       + 357 22 849 313
  limited.
                                                    Email:     press@marcusevanscy.com


                                                    All rights reserved. The above content may be republished or reproduced. Kindly
                                                    inform us by sending an email to press@marcusevanscy.com




About Capish

Capish is a Swedish Knowledge Management Service Organisation founded in 2001. We can give non-data literate experts
immediate access to all clinical and non-clinical information through easy-to-use web-based interactive graphical interfaces for
searching and also interactive statistical tools for analyses. Capish will shortly be available for prospective trials.


www.capishknowledge.com


About marcus evans Summits

marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss
strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to
individually tailor their schedules of keynote presentations, think tanks, seminars and one-on-one business meetings.


For more information, please visit: www.marcusevans.com


Upcoming Events

Discovery Summit (Europe) - www.discovery-summit.com


Discovery Summit (North America) - www.thediscoverysummit.com


Evolution Summit (Europe) - www.evolution-summit.com


Evolution Summit (North America) - www.evolutionsummit.com



To view the web version of this interview please click here:
www.pharmaceuticalseries.com/StaffanGestreliusJerkerRingstrom

Weitere ähnliche Inhalte

Andere mochten auch (9)

Manual siemens campana lf457ca60
Manual siemens    campana lf457ca60Manual siemens    campana lf457ca60
Manual siemens campana lf457ca60
 
PM 14 2010.pdf
PM 14 2010.pdfPM 14 2010.pdf
PM 14 2010.pdf
 
Doc1
Doc1Doc1
Doc1
 
Jobbik Hírlevél 2012. 11. szám
Jobbik Hírlevél 2012. 11. számJobbik Hírlevél 2012. 11. szám
Jobbik Hírlevél 2012. 11. szám
 
Green jeanpdf
Green jeanpdfGreen jeanpdf
Green jeanpdf
 
Liatrabajo
LiatrabajoLiatrabajo
Liatrabajo
 
Relato
RelatoRelato
Relato
 
Food Hygiene certificate 2
Food Hygiene certificate 2Food Hygiene certificate 2
Food Hygiene certificate 2
 
Programa anual 2012 de la EIS
Programa anual 2012 de la EISPrograma anual 2012 de la EIS
Programa anual 2012 de la EIS
 

Mehr von Life Sciences Network marcus evans

Mehr von Life Sciences Network marcus evans (20)

The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
 
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClisOptimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
 
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKHow Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
 
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
 
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
 
Turning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessTurning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for Success
 
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
 
Business Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENABusiness Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENA
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
 
Where marcus evans fits in our business development mix
Where marcus evans fits in our business development mixWhere marcus evans fits in our business development mix
Where marcus evans fits in our business development mix
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
 
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic RhinoconjunctivitisCRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
 
Grow Your Business
Grow Your BusinessGrow Your Business
Grow Your Business
 

Kürzlich hochgeladen

Jual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg Pfizer
Jual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg PfizerJual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg Pfizer
Jual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg Pfizer
Pusat Herbal Resmi BPOM
 
ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...
ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...
ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...
brennadilys816
 
What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...
srcw2322l101
 
Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.
Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.
Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.
daisycvs
 
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
prakheeshc
 
PEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTAR
PEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTARPEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTAR
PEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTAR
doktercalysta
 

Kürzlich hochgeladen (20)

Goal Presentation_NEW EMPLOYEE_NETAPS FOUNDATION.pptx
Goal Presentation_NEW EMPLOYEE_NETAPS FOUNDATION.pptxGoal Presentation_NEW EMPLOYEE_NETAPS FOUNDATION.pptx
Goal Presentation_NEW EMPLOYEE_NETAPS FOUNDATION.pptx
 
stock price prediction using machine learning
stock price prediction using machine learningstock price prediction using machine learning
stock price prediction using machine learning
 
MichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdfMichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdf
 
PitchBook’s Guide to VC Funding for Startups
PitchBook’s Guide to VC Funding for StartupsPitchBook’s Guide to VC Funding for Startups
PitchBook’s Guide to VC Funding for Startups
 
Progress Report - UKG Analyst Summit 2024 - A lot to do - Good Progress1-1.pdf
Progress Report - UKG Analyst Summit 2024 - A lot to do - Good Progress1-1.pdfProgress Report - UKG Analyst Summit 2024 - A lot to do - Good Progress1-1.pdf
Progress Report - UKG Analyst Summit 2024 - A lot to do - Good Progress1-1.pdf
 
Jual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg Pfizer
Jual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg PfizerJual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg Pfizer
Jual Obat Aborsi Di Sibolga wa 0851/7541/5434 Cytotec Misoprostol 200mcg Pfizer
 
ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...
ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...
ابو ظبي اعلان | - سايتوتك في الامارات حبوب الاجهاض للبيع ف حبوب الإجهاض ... ا...
 
Beyond Numbers A Holistic Approach to Forensic Accounting
Beyond Numbers A Holistic Approach to Forensic AccountingBeyond Numbers A Holistic Approach to Forensic Accounting
Beyond Numbers A Holistic Approach to Forensic Accounting
 
What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...
 
Pay after result spell caster (,$+27834335081)@ bring back lost lover same da...
Pay after result spell caster (,$+27834335081)@ bring back lost lover same da...Pay after result spell caster (,$+27834335081)@ bring back lost lover same da...
Pay after result spell caster (,$+27834335081)@ bring back lost lover same da...
 
Raising Seed Capital by Steve Schlafman at RRE Ventures
Raising Seed Capital by Steve Schlafman at RRE VenturesRaising Seed Capital by Steve Schlafman at RRE Ventures
Raising Seed Capital by Steve Schlafman at RRE Ventures
 
Elevate Your Online Presence with SEO Services
Elevate Your Online Presence with SEO ServicesElevate Your Online Presence with SEO Services
Elevate Your Online Presence with SEO Services
 
Exploring-Pipe-Flanges-Applications-Types-and-Benefits.pptx
Exploring-Pipe-Flanges-Applications-Types-and-Benefits.pptxExploring-Pipe-Flanges-Applications-Types-and-Benefits.pptx
Exploring-Pipe-Flanges-Applications-Types-and-Benefits.pptx
 
Inside the Black Box of Venture Capital (VC)
Inside the Black Box of Venture Capital (VC)Inside the Black Box of Venture Capital (VC)
Inside the Black Box of Venture Capital (VC)
 
Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.
Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.
Abortion pills in Muscut<Oman(+27737758557) Cytotec available.inn Kuwait City.
 
Innomantra Viewpoint - Building Moonshots : May-Jun 2024.pdf
Innomantra Viewpoint - Building Moonshots : May-Jun 2024.pdfInnomantra Viewpoint - Building Moonshots : May-Jun 2024.pdf
Innomantra Viewpoint - Building Moonshots : May-Jun 2024.pdf
 
How Do Venture Capitalists Make Decisions?
How Do Venture Capitalists Make Decisions?How Do Venture Capitalists Make Decisions?
How Do Venture Capitalists Make Decisions?
 
How to refresh to be fit for the future world
How to refresh to be fit for the future worldHow to refresh to be fit for the future world
How to refresh to be fit for the future world
 
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
 
PEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTAR
PEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTARPEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTAR
PEMATANG SIANTAR 0851/8063/4797 JUAL OBAT ABORSI CYTOTEC PEMATANG SIANTAR
 

Unlocking Data for Profitable Clinical Development

  • 1. Unlocking Data for Profitable Clinical Development Staffan Gestrelius: Scientists need to then all of a sudden you have to focus probe and analyze data the way the on the patient and what genetic financial sector does. To make better patterns or biomarkers he reacts to, this decisions and learn more about their will be an important turning point in compounds and patients, they must drug development. unlock data throughout the study and not just at the end. This will become even more important with personalized medicine. How can clinical data become a Knowledge knowledge asset? directly impacts Jerker Ringstrom: One of the most important words in this space is profitability “knowledge”. To turn data into a knowledge asset, it must be put into perspective. Scientists need constant feedback when deciding whether to Can it help scientists be more continue with a program or to make innovative? How? amendments. Jerker Ringstrom: Scientists can get If you look at a clinical trial protocol, it new ideas for indications by better usually mirrors the situation of the analyzing data. More drugs today are study six to eight months before it being used in new formulations and for ended. This means there was time to new indications, but finding these new Interview with: Staffan Gestrelius, make valuable changes to the design indications is proving to be challenging. President and Chief Executive and improve the quality of the trial. Officer & Jerker Ringstrom, Head of How is this approach more Business Development, Capish How could this enhance safety? profitable? Staffan Gestrelius: If you have a system Staffan Gestrelius: This will be a Scientists must unlock and analyze data that continuously watches over patients knowledge game. It will become crucial throughout the clinical trial, according and gives you access to graphs and to know everything about a specific to Staffan Gestrelius, President and statistics, you can keep track of adverse drug. This approach is more profitable Chief Executive Officer and Jerker events and drug associated adverse because people are not willing to pay for Ringstrom, Head of Business effects. The earlier this is done, the a drug that only has a 50 per cent Development, Capish. From a solution better. chance of curing them. The reason why provider company at the marcus evans many companies are troubled today is Evolution Summit 2012, in North Jerker Ringstrom: This also helps because they do not have good enough America and the Evolution Summit pharmaceutical companies be patient treatments. 2012 in Europe, Gestrelius and centric. When you develop a new drug, Ringstrom discuss how knowledge you need to come up with a diagnostic Knowledge directly impacts profitability. directly impacts the profitability of tool. The patient plays a more central Pharmaceutical companies should focus clinical development. role than before, as the diagnosis will be more on knowledge than on showing the torch through the darkness. I that the drug is not dangerous, simply What role can Business Intelligence emphasize darkness, because when you to get it approved by the FDA. This will tools play in clinical development? focus on means and standard deviations not be enough.
  • 2. For more information please send an email to info@marcusevanscy.com or visit The Pharma Network - the event websites below: marcus evans Summits group delivers peer-to-peer information Evolution Summit 2012 - North America: www.evolutionsummit.com on strategic matters, professional trends and breakthrough Evolution Summit 2012 - Europe: www.evolution-summit.com innovations. Contact Please note that the Summit is a Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits closed business event and the Division number of participants strictly Tel: + 357 22 849 313 limited. Email: press@marcusevanscy.com All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.com About Capish Capish is a Swedish Knowledge Management Service Organisation founded in 2001. We can give non-data literate experts immediate access to all clinical and non-clinical information through easy-to-use web-based interactive graphical interfaces for searching and also interactive statistical tools for analyses. Capish will shortly be available for prospective trials. www.capishknowledge.com About marcus evans Summits marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-on-one business meetings. For more information, please visit: www.marcusevans.com Upcoming Events Discovery Summit (Europe) - www.discovery-summit.com Discovery Summit (North America) - www.thediscoverysummit.com Evolution Summit (Europe) - www.evolution-summit.com Evolution Summit (North America) - www.evolutionsummit.com To view the web version of this interview please click here: www.pharmaceuticalseries.com/StaffanGestreliusJerkerRingstrom